EQT Life Sciences
- 6
- Portfolio companies on reccy
- 1
- Hiring now
- 3
- Open roles in the portfolio
- Apr 2026
- Latest portfolio round
Hiring now in the portfolio3
Apply on each company's sitePortfolio on reccy6
From company funding records- Series D · $42M · Mar 20243 roles
Phagenesis
Manchester, UK · Led a round · Series D · $42M · Mar 2024
- Debt Financing · $29.1M · Sep 2026None
Neurent Medical
Oranmore, Ireland · Led a round · Debt Financing · $29.1M · Sep 2026
- Post-IPO Equity · $47.8M · Apr 2026None
ONWARD Medical
Eindhoven, The Netherlands · Led a round · Post-IPO Equity · $47.8M · Apr 2026
- Debt Financing · $35M · Mar 2026None
Neuros Medical
Willoughby, Ohio · Led a round · Debt Financing · $35M · Mar 2026
- Venture Round · $23.9M · Mar 2025None
Perfuze
Newcastle, Galway, Ireland · Led a round · Venture Round · $23.9M · Mar 2025
- Series C · $32.6M · Jan 2024None
Onera
Eindhoven, The Netherlands · Led a round · Series C · $32.6M · Jan 2024
Recent rounds in the portfolio
Crunchbase funding records- Apr 2026
ONWARD Medical · Post-IPO Equity $47.8MLead
- Jul 2025
Neuros Medical · Series D $56MLead
- Mar 2025
Perfuze · Venture Round $23.9MLead
With EarlyBird, Seroba Life Sciences, SV Health Investors
- Mar 2024
ONWARD Medical · Post-IPO Equity $21.9MLead
With Wellington Partners
- Mar 2024
Phagenesis · Series D $42MLead
- Jan 2024
Onera · Series C $32.6MLead
With Gimv
- Feb 2022
Perfuze · Series A $25.7MLead
With Seroba Life Sciences, SV Health Investors
- Jan 2021
Neurent Medical · Series B $25MLead
With Atlantic Bridge, LSP